NOVUGEN PHARMA SDN
GenericsNOVUGEN PHARMA SDN is a generic drug manufacturer focused on Cardiovascular.
NOVUGEN PHARMA SDN's Key Drugs
NOVUGEN PHARMA SDN's core commercial portfolio centers on SACUBITRIL AND VALSARTAN, spanning Cardiovascular — its most strategically important drugs approved in the last 15 years.
NOVUGEN PHARMA SDN's Recent FDA Approvals
New NDA/BLA approvals for NOVUGEN PHARMA SDN over the last two years — novel drugs only, excluding generics and label supplements.
NOVUGEN PHARMA SDN's Therapeutic Areas
NOVUGEN PHARMA SDN's approved drugs and pipeline span 1 therapeutic area, led by Cardiovascular, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
NOVUGEN PHARMA SDN's Top Competitors
NOVUGEN PHARMA SDN's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
NOVUGEN PHARMA SDN Pipeline Snapshot
Active clinical trials for NOVUGEN PHARMA SDN across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SACUBITRIL AND VALSARTAN leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2025-07-16
- Latest
- 2025-07-16
- Applications
- 1